A Study to Target the Type I IFN Receptor by Administrating Anifrolumab in RA Patients With a High IFN Signature (TarIFNiRA)

Name: A Study to Target the Type I IFN Receptor by Administrating Anifrolumab in RA Patients With a High IFN Signature (TarIFNiRA)
Published: 2018
License: Public Domain

Josef Smolen, Univ. Prof. Dr. · 2018

ClinicalTrials.gov · Datasets · License: Public Domain · 2018

Open Source ↗

rheumatoid-arthritis

rheumatoid arthritis, ra, ifn-signature, anifrolumab, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Study to Target the Type I IFN Receptor by Administrating Anifrolumab in RA Patients With a High IFN Signature (TarIFNiRA)

Related documents